Senti Biosciences (NASDAQ:SNTI) Releases Earnings Results, Beats Estimates By $0.22 EPS

Senti Biosciences (NASDAQ:SNTI) announced its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.22, FiscalAI reports.

Senti Biosciences Price Performance

SNTI stock traded up $0.08 during midday trading on Thursday, hitting $1.05. 513,178 shares of the stock traded hands, compared to its average volume of 195,320. The firm has a market cap of $32.54 million, a P/E ratio of -0.33 and a beta of 2.09. The stock’s fifty day simple moving average is $0.95 and its 200-day simple moving average is $1.23. Senti Biosciences has a 1-year low of $0.77 and a 1-year high of $3.88.

Institutional Trading of Senti Biosciences

Several institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in Senti Biosciences in the fourth quarter valued at approximately $46,000. Jane Street Group LLC acquired a new stake in Senti Biosciences in the fourth quarter valued at approximately $40,000. Citadel Advisors LLC acquired a new stake in Senti Biosciences in the third quarter valued at approximately $117,000. Armistice Capital LLC acquired a new stake in Senti Biosciences in the second quarter valued at approximately $1,883,000. Finally, Geode Capital Management LLC grew its holdings in Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares during the period. 25.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SNTI. Chardan Capital cut their price objective on Senti Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Wall Street Zen upgraded shares of Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Senti Biosciences currently has an average rating of “Moderate Buy” and an average price target of $8.50.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.